Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 14;8(1):e001519. doi: 10.1136/bmjdrc-2020-001519

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Alleviation of tight junction protein disruption by lutein treatment in the retinas of the Ins2^Akita/+ mice. (A, B) Western blot results showing occludin expression levels in the wild-type, untreated Ins2^Akita/+, lutein-treated Ins2^Akita/+ (4.2 mg/kg/day, Akita+L4.2) and lutein-treated Ins2^Akita/+ (8.4 mg/kg/day, Akita+L8.4) mice at 6.5 months of age. (C, D) Western blot results showing occludin expression levels in the four experimental groups at 9 months of age. Occludin expression level in each group was normalized with β-actin. Fold changes relative to wild-type control are shown. n=6–7. Data are presented as mean±SEM. One-way ANOVA followed by Tukey’s multiple comparison test. **P<0.01, ***p<0.001. ****p<0.0001. ANOVA, analysis of variance.